Proactive Investors
13 Oct 2026, 10:42 UTC · 1h ago
Haydale shares drop 12% as revenue falls short of expectations
Impact · against what's priced in
Haydale's significant revenue miss and wider-than-expected losses outweigh the operational benefits of the Quidos JV and margin expansion. Arecor's progress on its insulin and GLP-1 pipeline is a positive incremental update, though less material than Haydale's financial miss.
- HAYD−0.70
No priced-in read yet
- In context
The 37.5% revenue miss (£5m vs £8m expected) and a larger adjusted loss of £2.69m create immediate downward pressure, which is only partially mitigated by a lower breakeven threshold of £10m via the Quidos JV.
Read from the article alone
